# US 2005/0032699 A1 · Composition of a VEGF antagonist and an anti-proliferative agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032699 A1
- Document ID: US20050032699A1
- Status: Published application
- Kind: A1
- Application number: 10/897,802
- Filed: 2004-07-23
- Published: 2005-02-10
- Earliest claimed: 2003-07-25
- Assignees: Regeneron Pharmaceuticals, Inc.
- Inventors: Jocelyn Holash; Robert Jaffe; Limin Hu; George Yancopoulos
- Web page: https://patentgrep.com/patent/US20050032699A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/179: {for growth factors; for growth regulators}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, such as a VEGF trap, an anti-proliferative agent, such as taxol, and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A method of treating cancer in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent such that the cancer is treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the VEGF antagonist is a VEGF trap.

### Claim 3 (depends on 2)

The method of claim 2, wherein the VEGF trap is VEGFR1R2-FcΔC1(a) or Flt1D2.Flk1D3.FcΔC1(a).

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-proliferative agent is a microtubule stabilizing agent.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-proliferative agent is paclitaxel, or a derivative, analogue, or mixture thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-proliferative agent is a platinum-based chemotherapeutic selected from the group consisting of cisplatin, carboplatin, and iproplatin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) and the anti-proliferative agent is paclitaxel.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 9

A method of treating cancer in a subject in need thereof, comprising administering to the subject a vascular endothelial growth factor (VEGF) antagonist and an anti-proliferative agent such that the cancer is treated, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) or Flt1D2.Flk1D3.FcΔC1(a), and the anti-proliferative agent is a paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is a human subject.

### Claim 10

A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent, wherein the growth of the tumor is reduced.

### Claim 11 (depends on 10)

The method of claim 10, wherein the VEGF antagonist is a VEGF trap.

### Claim 12 (depends on 11)

The method of claim 11, wherein the VEGF trap is VEGFR1R2-FcΔC1(a) or Flt1D2.Flk1D3.FcΔC1(a).

### Claim 13 (depends on 10)

The method of claim 10, wherein the anti-proliferative agent is paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.

### Claim 14 (depends on 10)

The method of claim 10, wherein the anti-proliferative agent is a platinum-based chemotherapeutic selected from the group consisting of cisplatin, carboplatin, and iproplatin.

### Claim 15 (depends on 10)

The method of claim 10, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) and the anti-proliferative agent is paclitaxel.

### Claim 16

A method of inhibiting tumor growth in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein tumor growth is inhibited.

### Claim 17 (depends on 16)

The method of claim 16, wherein administration is subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, intranasal, epidural, or oral.

### Claim 18

A method of inhibiting or reducing tumor growth in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein tumor growth is inhibited, wherein the VEGF antagonist is a VEGF trap, and the anti-proliferative agent is selected from the group consisting of paclitaxel, docetaxel or a derivative, analogue, or mixture of paclitaxel and a platinum-based chemotherapeutic.

### Claim 19

A pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, an anti-proliferative agent, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the VEGF antagonist a VEGF trap.

### Claim 21 (depends on 20)

The method of claim 20, wherein the VEGF trap is VEGFR1R2-FcΔC1(a) or Flt1D2.Flk1D3.FcΔC1(a).

### Claim 22 (depends on 19)

The pharmaceutical composition of claim 19, wherein the anti-proliferative agent is paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.

### Claim 23

A method of reducing the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect, comprising administering the chemotherapeutic agent with a VEGF antagonist.

### Claim 24 (depends on 23)

The method of claim 23, wherein the chemotherapeutic agent is an anti-proliferative agent selected from the group consisting of paclitaxel, or a derivative, analogue, or a mixture of paclitaxel and a platinum-based chemotherapeutic.

### Claim 25 (depends on 23)

The method of claim 23, wherein the VEGF antagonist a VEGF trap selected from the group consisting of VEGFR1R2-FcΔC1(a) and Flt1D2.Flk1D3.FcΔC1(a).

### Claim 26 (depends on 23)

The method of claim 23, wherein the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect is reduced by at least 20%.

### Claim 27 (depends on 26)

The method of claim 26, wherein the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect is reduced by about 30-50%.

### Claim 28

An article of manufacturing, comprising:
(a) packaging material; and
(b) a pharmaceutical agent contained within the packaging material, wherein the pharmaceutical agent comprises at least one dose of vascular endothelial growth factor (VEGF) trap and at least one anti-proliferative agent, and wherein the packaging material indicates that the VEGF antagonist and anti-proliferative agent can be used for treating cancer or reducing tumor growth.
